Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
02. August 2022 15:30 ET
|
Athira Pharma, Inc.
Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small molecule positive modulators of HGF/MET reverse...
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022
25. Juli 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
22. Juni 2022 07:00 ET
|
Athira Pharma, Inc.
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together...
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
07. Juni 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
19. Mai 2022 12:06 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
16. Mai 2022 16:49 ET
|
Athira Pharma, Inc.
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16,...
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
16. Mai 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
12. Mai 2022 16:05 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 12, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
11. Mai 2022 16:15 ET
|
Athira Pharma, Inc.
Urges Shareholders to Vote TODAY “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
09. Mai 2022 07:00 ET
|
Athira Pharma, Inc.
– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...